IDEAYA Biosciences宣布其潜在首创Mat2a抑制剂Ide397与Trodelvy®联合治疗Mtap缺失尿路上皮癌的1/2期试验获得积极数据

美股速递
Sep 08, 2025

IDEAYA Biosciences宣布其潜在首创Mat2a抑制剂Ide397与Trodelvy®联合治疗Mtap缺失尿路上皮癌的1/2期试验获得积极数据

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10